Literature DB >> 7739176

[Obstructive sleep apnea syndrome associated with superior vena cava syndrome].

G Fuyuno1, R Kobayashi, R Iga, H Nomori, K Kodera, S Morinaga.   

Abstract

A 43-year-old man was admitted suffering from dyspnea on exertion and edema of the neck and face. Chest X-ray film and CT scan revealed a mediastinal tumor and a right pleural effusion. A biopsy of the tumor revealed poorly differentiated carcinoma. Severe snoring at night and excessive daytime sleepiness were noticed after admission. Nocturnal oxygen desaturation was documented with a pulse oximeter, and obstructive sleep apnea syndrome was diagnosed on the basis of results of respiratory inductive plethysmography. The severity of snoring and oxygen desaturation during sleep correlated well with the progression of facial swelling. Combination chemotherapy (carboplatin 300 mg/m2 day 1, vindesine sulfate 3 mg/m2 day 1 and 8) was started but no improvement was seen. An expandable metallic stent was inserted into the stenotic vena cava, and the facial swelling, snoring, and oxygen desaturation during sleep were promptly relieved. In this case, obstructive sleep apnea was caused by edema and vascular congestion in the upper airway, and by the decrease in pharyngeal inspiratory muscle function caused by superior vena cava syndrome.

Entities:  

Mesh:

Year:  1995        PMID: 7739176

Source DB:  PubMed          Journal:  Nihon Kyobu Shikkan Gakkai Zasshi        ISSN: 0301-1542


  2 in total

1.  Worsening of Obstructive Sleep Apnea Associated with Catheter-Related Superior Vena Cava Syndrome.

Authors:  Marie Jouvenot; Serge Willoteaux; Nicole Meslier; Frédéric Gagnadoux
Journal:  J Clin Sleep Med       Date:  2015-06-15       Impact factor: 4.062

2.  Coexistence of Obstructive Sleep Apnea and Superior Vena Cava Syndromes Due to Substernal Goitre in a Patient With Respiratory Failure: A Case Report.

Authors:  Mehtap Tunc; Hilal Sazak; Bulent Karlilar; Fatma Ulus; Irfan Tastepe
Journal:  Iran Red Crescent Med J       Date:  2015-05-31       Impact factor: 0.611

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.